Tag Archives: Cancer Genetics

Cancer Genetics (CGIX) Gets a Hold Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Hold rating on Cancer Genetics (CGIX – Research Report) today. The company’s shares opened today at $0.45, close to its 52-week low of $0.30. McCarthy wrote: “Cancer Genetics (CGI) reported 3Q18 with revenues

Maxim Group Maintains a Hold Rating on Cancer Genetics (CGIX)

In a report released today, Jason McCarthy from Maxim Group maintained a Hold rating on Cancer Genetics (NASDAQ: CGIX). The company’s shares opened today at $0.98, close to its 52-week low of $0.82. McCarthy observed: “Cancer Genetics (CGI) announced a

Cancer Genetics (CGIX) Receives a Hold from Maxim Group

In a report released today, Jason McCarthy from Maxim Group maintained a Hold rating on Cancer Genetics (NASDAQ: CGIX). The company’s shares opened today at $0.94, close to its 52-week low of $0.82. McCarthy wrote: “Cancer Genetics reported revenue of

Analyst Explains Why They Cancer Genetics Downgrade Their Cancer Genetics Rating

In a report released today, Jason McCarthy from Maxim Group downgraded Cancer Genetics (NASDAQ: CGIX) to Hold. The company’s shares closed yesterday at $1.65, close to its 52-week low of $1.55. McCarthy noted: “We are downgrading CGIX to Hold, from

Maxim Group Initiates a Buy Rating on Cancer Genetics

Cancer Genetics (NASDAQ: CGIX) received a Buy rating and a $6 price target from Maxim Group analyst Jason McCarthy today. The company’s shares closed yesterday at $2.15. McCarthy wrote: “As the paradigm in oncology shifts to immune therapy with CAR-T,

Cancer Genetics Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cancer Genetics (NASDAQ: CGIX), with a price target of $6. The company’s shares closed yesterday at $2.85. According to TipRanks.com, Selvaraju is ranked 0 out